| Phenotype | Patients / 8,749 | Reported percent | Suggested HPO term label |
|---|---:|---:|---|
| Itching and pain | 6,784 | 77.54% | Pruritus; Pain |
| Vesicles or pustules | 3,160 | 36.12% | Vesicle; Pustule |
| Urticaria or papules | 2,916 | 33.33% | Urticaria; Papule |
| Systemic allergy | 658 | 7.52% | Systemic anaphylaxis |
| Fever | 232 | 2.65% | Fever |
| Dizziness or headache | 173 | 1.98% | Dizziness; Headache |
| Shock | 102 | 1.17% | Anaphylactic shock |
| Localized allergic lymphadenopathy | 82 | 0.94% | Lymphadenopathy |
| Transient speech loss | 66 | 0.75% | Loss of speech |
| Death | 3 | 0.03% | Death |
| **Ascertainment and interpretation** | **Mixed hospital records, published studies, and online news reports—not a population-based sample** | **Categories overlap; shock is nested within systemic allergy, so percentages are neither mutually exclusive nor population risks.** | **Chen et al., 2026** (pqac-00000034, pqac-00000035) |


*Table: Clinical phenotypes among 8,749 assembled fire-ant sting cases reported by Chen et al. (2026). These mixed-source frequencies are descriptive rather than population-based; the corrected projected systemic-allergy count is 52,600, not the abstract's erroneous 526,000.*